- Home
- PCVX vs KBR Comparison
PCVX vs KBR Comparison
Compare PCVX & KBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | KBR |
|---|---|---|
| Founded | 2013 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 4.8B |
| IPO Year | 2020 | 2006 |
Fundamental Metrics
Financial Performance| Metric | PCVX | KBR |
|---|---|---|
| Price | $60.39 | $37.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $98.33 | $53.14 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.75% |
| EPS Growth | N/A | ★ 15.05 |
| EPS | N/A | ★ 3.21 |
| Revenue | N/A | ★ $5,767,000,000.00 |
| Revenue This Year | N/A | $4.56 |
| Revenue Next Year | N/A | $5.11 |
| P/E Ratio | ★ N/A | $11.73 |
| Revenue Growth | N/A | ★ 2.27 |
| 52 Week Low | $28.09 | $35.62 |
| 52 Week High | $65.00 | $56.78 |
Technical Indicators
Market Signals| Indicator | PCVX | KBR |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 47.08 |
| Support Level | $42.30 | $36.19 |
| Resistance Level | $65.00 | $38.34 |
| Average True Range (ATR) | 2.19 | 1.10 |
| MACD | 0.57 | 0.25 |
| Stochastic Oscillator | 97.58 | 71.87 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
About KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is a global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: mission technology solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 36,000 people. The firm generated $7.8 billion in revenue in 2025.